As planned, Radius Health has raised $52 million in an IPO by offering 6.5 million shares at $8 per share. The company had recently updated its terms, formerly planning to offer 5 million shares at between $14 and $16 per share. Radius, which last raised $43 million of funding at a reported $200 million valuation in April 2013, lists on the NASDAQ under the symbol RDUS. Its backers included MPM Capital (24.6% pre-IPO stake), F2 Ventures (23.1%), Wellcome Trust (6.9%) and Brookside Capital (6.4%), among others. Radius ended its first day of trading at $8.01.
Several other biotech/pharma companies have very recently made IPO news, continuing the industry's impressive run in producing companies trying their luck in public markets. For example, four additional companies set terms for their offerings or announced plans to hit the public markets within the past week, including Zafgen, ZS Pharma, Syndax Pharmaceuticals and Pfenex.